etoposide has been researched along with xk 469 in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Al-Katib, AM; Mensah-Osman, EJ; Mohammad, RM; Osman, NI; Wu, HY | 1 |
Al-Katib, AM; Mensah-Osman, EJ; Mohammad, RM | 1 |
2 other study(ies) available for etoposide and xk 469
Article | Year |
---|---|
2-[4-(7-chloro-2-quinoxalinyloxyphenoxy]-propionic acid (XK469), an inhibitor of topoisomerase (Topo) IIbeta, up-regulates Topo IIalpha and enhances Topo IIalpha-mediated cytotoxicity.
Topics: Antigens, Neoplasm; Blotting, Western; Culture Media, Serum-Free; DNA; DNA Topoisomerases, Type II; DNA-Binding Proteins; Enzyme Inhibitors; Etoposide; Humans; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Cell; Microscopy, Confocal; Microscopy, Fluorescence; Neoplasm Transplantation; Protein Isoforms; Quinoxalines; Time Factors; Tumor Cells, Cultured; Up-Regulation; Waldenstrom Macroglobulinemia | 2002 |
Preclinical evaluation of 2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]-propionic acid as a modulator of etoposide in human Waldenstrom's macroglobulinemia xenograft model.
Topics: Animals; Cell Division; Etoposide; Humans; Mice; Mice, SCID; Quinoxalines; Transplantation, Heterologous; Waldenstrom Macroglobulinemia | 2003 |